The first and only FDA-approved pill proven to increase a woman’s sex drive.

Side effects of Addyi (flibanserin)
What should I do if I forget a dose?
Reward Processing as a Symptom Dimension in Psychiatric Disorders
Uses for flibanserin

Drug dosage is adjusted according to blue tablets the patient genotype.

Global availability varies; approved in the US, Canada, and some other countries.
Not approved in the European Union by the EMA as of current knowledge.
Different brand names may be used in countries where it is marketed.
Importing for personal use from other countries carries risks and is often illegal.
Counterfeit versions of the medication are a potential danger.
Patients should only obtain it from a certified, licensed pharmacy.
Telemedicine may be used for consultations but REMS requirements still apply.
The future of flibanserin may involve generic competition reducing cost.
Research into its potential effects on other conditions (e.g., depression) is limited.

In patients with the CYP2C9 *3/*3 genotype, do not use the siponimod (FDA, 2021).

Side effects of Addyi (flibanserin)

Higher systemic concentrations and the chance of adverse reactions are possible with UGT1A1 *28/*28 (poor metabolizers) (neutropenia). Monitoring for adverse reactions and tolerance to treatment are recommended (FDA, 2021). Siponimod is a drug that helps patients with relapsing multiple sclerosis. Lowering the siponimod dose is recommended for CYP2C9 *1/*3, *2/*3 genotypes and avoiding siponimod for the CYP2C9 *3/*3 genotype in the DPWG guideline (Whirl-Carrillo et al., 2012; Abdullah-Koolmees et al., 2020). Higher systemic concentrations are associated with CYP2C9 intermediate or weak metabolizers. Succinylcholine is a depolarizing skeletal muscle relaxant that is used to relax skeletal muscles during intubation, mechanical ventilation, and surgical procedures. In people who are susceptible to malignant hyperthermia, the CPIC Dosing Guideline suggests that halogenated volatile anesthetics including desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, and the depolarizing muscle relaxants succinylcholine be avoided (MHS) (Gonsalves et al., 2019). Higher systemic concentrations and a higher risk of adverse reactions are associated with BCHE intermediate or weak metabolizers (prolonged neuromuscular blockade).

Product	Dosage	Quantity + Bonus	Price
Levitra Original	20mg	76 + 4 Pills	344.39€ 327.99€
Kamagra Oral Jelly	100mg	110 + 9 Sachets	334.87€ 318.92€
Tadalista Super Active	20mg	20 + 4 Pills	92.35€ 87.95€
Cialis Soft Tabs	20mg	10 Pills	39.03€ 37.17€
Cialis Generic	20mg	180 + 10 Pills	254.09€ 241.99€
Kamagra Oral Jelly	100 mg	21 Sachets	95.92€ 91.35€
Viagra Super Active	100mg	30 + 6 Pills	64.09€ 61.04€
Cialis Soft Tabs	20mg	60 + 4 Pills	159.37€ 151.78€
Viagra Oral Jelly	100mg	220 + 18 Sachets	562.28€ 535.50€
Levitra Original	20mg	22 + 2 Pills	138.55€ 131.95€

Avoid using it if you have a slow metabolizer. To determine sensitivity, administer a test dose and then slowly infuse the medication (FDA, 2021).

Direct comparison trials between flibanserin and bremelanotide are lacking.
Choice of treatment depends on patient preference, risk profile, and cost.
Psychological and interpersonal factors are important contributors to HSDD.
Combining medication with sex therapy or counseling may improve outcomes.
Flibanserin does not increase libido in individuals without HSDD.
It is not approved or intended for use as a recreational or enhancement drug.
Off-label use, such as in postmenopausal women or men, is not supported by evidence.
Healthcare providers must complete an online knowledge assessment for REMS certification.
Certification must be renewed periodically according to the REMS program.

Tacrolimus is a calcineurin inhibitor that is used to treat mild to serious atopic dermatitis and to prevent organ transplant rejection.

Feature	Flibanserin	Bremelanotide	Vyleesi
Approved for HSDD	Yes	No	Yes
Administration Route	Oral	Injectable	Injectable
Usage Frequency	Daily	As needed	As needed
Main Side Effects	Dizziness, nausea	Nausea, flushing	Nausea, reactions at injection site

Recommendation according to the CPIC dosing guideline for tacrolimus is raising the starting dose by 1.5 to 2 times the recommended starting dose, but the total starting dose does not exceed 0.3 mg/kg/day in patients with CYP3A5 intermediate or extensive metabolizers.

What should I do if I forget a dose?

Piroxicam is a nonsteroidal anti-inflammatory drug (NSAID) that is used to relieve the effects of osteoarthritis and rheumatoid arthritis. Patients with CYP2C9 poor and intermediate metabolizers and an activity score of 1 should select an alternative therapy that is not metabolized by CYP2C9 or is not substantially impacted in vivo by CYP2C9 genetic variants or choose an NSAID that is metabolized by CYP2C9 but has a shorter half-life (Theken et al., 2020). CYP2C9 intermediate or poor metabolizers result in higher systemic concentrations. Consideration of reducing the dosage in poor metabolizers is recommended (FDA, 2021; Theken et al., 2020). Pitolisant is a histamine H3 receptor antagonist and inverse agonist used to treat narcolepsy in adults (Li and Yang, 2020).

Key Takeaways

Pitolisant (WAKIX) has an FDA-approved drug label that dose reduction is recommended in patients who are considered to be weak CYP2D6 metabolizers because their pitolisant concentrations are higher than typical CYP2D6 metabolizers. For CYP2D6 weak metabolizers, the maximum recommended dose is 17.8 mg once daily (Whirl-Carrillo et al., 2012). CYP2D6 poor metabolizers result in higher systemic concentrations. Using the lowest starting dosage is recommended (FDA, 2021). It is used to treat paroxysmal atrial fibrillation/flutter and ventricular arrhythmias.

Features and Benefits

Propafenone doses should be reduced by 70% for CYP2D6 poor metabolizers, and drug plasma concentrations should be monitored or an alternative medication should be used for CYP2D6 intermediate and ultrarapid metabolizers (Whirl-Carrillo et al., 2012; Dean, 2017a). Poor metabolizers of CYP2D6 have higher systemic concentrations and a higher risk of adverse reactions (arrhythmia). Sacituzumab govitecan works by targeting TROP-2-expressing cancer cells with a humanized antibody (RS7), then being internalized and releasing the topoisomerase I inhibitor SN-38 to trigger DNA damage-mediated apoptosis. Patients who are homozygous for the UGT1A1 *28 allele are at an elevated risk of neutropenia after starting sacituzumab govitecan-hziy (TRODELVY) therapy. Patients with low UGT1A1 activity should be closely monitored for serious neutropenia (Whirl-Carrillo et al., 2012; Nelson et al., 2021). Dose changes can also be driven by therapeutic medication control (Birdwell et al., 2015; Zhang et al., 2018).

Reward Processing as a Symptom Dimension in Psychiatric Disorders

Tolerability can necessitate dose reductions for intermediate metabolizers. For both genes, intermediate metabolizers may necessitate more drastic dosage reductions (FDA, 2021). Increasing the starting daily dose and to monitoring efficacy in CYP2C19 ultrarapid metabolizer is recommended in the CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole. In the treatment of Helicobacter pylori (H. pylori) infection and erosive esophagitis with CYP2C19 rapid and natural metabolizers, increasing the dose after initiation with the usual starting daily dose may be considered.

Oral Administration

For sex erection tablet chronic therapy (>12 weeks) and efficacy reached, a 50% reduction in daily dose is recommended for intermediate and low metabolizers (Lima et al., 2020). Using a fivefold higher dose for CYP2C19 ultrarapid metabolizers who are receiving H. pylori eradication therapy is suggested in Dutch Pharmacogenetics Working Group guideline. Awareness of reduced efficacy in CYP2C19 ultrarapid metabolizers with other indications and, if possible, the use a fivefold higher dose is recommended (Whirl-Carrillo et al., 2012). CYP2C19 poor metabolizers lead to higher systemic concentrations.

General drug facts

Consideration of dosage reduction in children who are poor metabolizers is recommended and dosage adjustment is not needed for poor metabolizers adult patients (FDA, 2021; El Rouby et al., 2018). Pimozide is an antipsychotic that is used to treat patients with Tourette's Disorder who have crippling motor and phonic tics. Patients who are intermediate metabolizers of CYP2D6 should receive no more than 80% of the standard maximum dose of pimozide, and those who are poor metabolizers of CYP2D6 should receive no more than 50% of the standard maximum dose (Whirl-Carrillo et al., 2012). Poor metabolizers of CYP2D6 result in higher systemic concentrations. Pimozide doses should not be increased more than 14 days and should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers (FDA, 2021; Rogers et al., 2012; Laje, 2013). Lower systemic concentrations, a lower likelihood of reaching target concentrations, and a higher risk of rejection are all consequences of CYP3A5 intermediate or mild metabolizers. Measurement of drug concentrations and dose regulating based on whole blood tacrolimus concentrations are recommended (FDA, 2021; Staatz and Tett, 2004).

Uses for flibanserin

Meloxicam is an NSAID that is used for treatment of osteoarthritis, rheumatoid arthritis in adults, and juvenile rheumatoid arthritis in children. According to the FDA-approved drug label for meloxicam (QMIIZ ODT), consideration of dose reduction, and monitoring the adverse effects are recommended in adult patients who are known or suspected poor CYP2C9 metabolizers (Whirl-Carrillo et al., 2012; Bae et al., 2011). CYP2C9 poor metabolizers lead to higher systemic concentrations. Consideration of dose reduction is recommended (FDA, 2021). Metoclopramide used in the treatment of gastroesophageal reflux disorder, inhibition of nausea and vomiting, and to promote gastric emptying as an antiemetic agent and dopamine D2 antagonist.

What should I do if I accidentally use too much Addyi?

Metoclopramide (REGLAN) is used as a short-term treatment option in gastroesophageal reflux in adult patients who have not responded to conventional therapy. Drug elimination is decreased in patients with CYP2D6 poor metabolizers, potentially raising the risk of adverse reactions, a reduced dose of the metoclopramide should prescribed to the patients (Whirl-Carrillo et al., 2012; Bae et al., 2020). Higher systemic concentrations and adverse reaction risk could associate with CYP2D6 poor metabolizers (FDA, 2021). Mercaptopurine is an antineoplastic agent used to treat acute lymphocytic leukemia. The CPIC Dosing Guideline states that patients with TPMT or NUDT15 poor metabolizers should consider a different agent or a drastic reduction in mercaptopurine dosage.

Brand Names

Patients who are intermediate metabolizers of TPMT or NUDT15 should start at 30–80% of the target dose (Relling et al., 2019; Zgheib et al., 2017). According to the Dutch Pharmacogenetics Working Group, choosing an alternative drug or decreasing the initial dose of mercaptopurine for patients with NUDT15 poor metabolizers, and reducing the initial dose for NUDT15 intermediate metabolizer patients are recommended (Whirl-Carrillo et al., 2012). The guideline also recommends choosing an alternative drug or decreasing the initial dose of mercaptopurine for patients with TPMT low metabolizers and reducing the initial dose for patients who are TPMT intermediate metabolizers (Whirl-Carrillo et al., 2012; Dean and Kane, 2012). According to the FDA guideline, TPMT and/or NUDT15 intermediate or poor metabolizers alter systemic active metabolite concentration and dosage requirements and lead to higher adverse reaction risk (myelosuppression). Initial dosages should be decreased in poor metabolizers; poor metabolizers tolerate 10% or less of the prescribed dose. Tetrabenazine is a vesicular monoamine transporter 2 (VMAT) inhibitor that is used to treat chorea in Huntington's disease patients.

Flibanserin is classified as a centrally acting serotonergic agent.
It is not a testosterone-based therapy, unlike some other treatments.
The FDA approval was based on studies showing increased sexual desire in women.
The medication can cause sleep disturbances, including somnolence.
Flibanserin has a potential for drug interactions with CYP3A4 inhibitors.
It is recommended to start treatment at least 4 weeks before expecting improvement.
Discontinuation of the drug normally leads to the loss of effects.
The drug's efficacy is modest compared to some male sexual dysfunction drugs.
Initiation of therapy involves screening for contraindications.

Patients that need doses greater than 50 mg per day should be genotyped for the drug metabolizing enzyme CYP2D6 to decide if they are a poor metabolizer (PM) or an extensive metabolizer (EM), according to the FDA-approved drug label for tetrabenazine (XENAZINE) (EM). Low doses should be given to people with CYP2D6 weak metabolizer genotypes (Whirl-Carrillo et al., 2012).

Side Effect	Frequency	Severity
Dizziness	Common	Mild to Moderate
Nausea	Common	Mild
Fatigue	Moderate	Mild
Sleepiness	Moderate	Mild

Poor metabolizers of CYP2D6 lead to higher systemic concentrations. The maximum single dose is 25 mg, and the total daily dose does not exceed 50 mg (FDA, 2021; Mehanna et al., 2013).

Reporting of adverse events is encouraged through the FDA MedWatch program.
Healthcare providers should report syncope, severe hypotension, or liver injury.
Post-marketing surveillance is critical for understanding rare, long-term risks.
Drug utilization reviews track prescribing patterns and potential misuse.
In case of suspected pregnancy, patients should contact their doctor immediately.
Animal studies showed developmental toxicity at doses much higher than human dose.
Lactation studies in animals showed excretion in milk; human data are lacking.
Decision to breastfeed while on flibanserin requires weighing potential risks.
The benefit for an individual patient must justify the potential risk to a fetus/infant.

Tioguanine is a purine analog antineoplastic agent that is used to induce and maintain remission in patients with acute nonlymphocytic anemias (FDA, 2021).